The incidence of lymphogranuloma venereum (LGV) -a sexually transmitted infection (STI) produced by the L1, L2, and L3 serovars of Chlamydia trachomatis- is increasing. The 8 patients in this case series were diagnosed with LGV in the STI unit of our dermatology department.  https://www.selleckchem.com/products/cc-90011.html  Our patients were younger than those in previously published case series, and on presentation they most often complained of tumorous masses (lymphadenopathy) in the groin. Dermatologists should be familiar with this disease. Samples must be taken correctly to ensure an accurate diagnosis and early treatment.
  There are no validated Spanish tools to assess symptom burden in pediatric cancer. The Pediatric Memorial Symptom Assessment Scale (Pediatric-MSAS) is an English valid multidimensional and comprehensive instrument.
 
  To validate Pediatric-MSAS-Spanish (MSAS-Child, MSAS-Teen, and MSAS-Caregiver versions) in patients with cancer treated in two public hospitals in Buenos Aires, Argentina.
 
  Cross-sectional study, classical psychometric theory. We recruited a convenience sample of 148 caregivers of children ≥ twoyears, 51 young children (seven to 12years), and 48 adolescents (≥13years). We assessed feasibility, comprehensibility, internal consistency, and convergent and known-groups validity.
 
  Pediatric-MSAS-Spanish was feasible, acceptable, and comprehensible. Reliability of MSAS-total and subscale scores was satisfactory (Cronbach alpha 0.90, 0.89, 0.71, respectively, for caregiver, teen, and child MSAS-total score). MSAS-total caregiver, teen, and child scores met a priori criteria for convergent validity cen with cancer. Validity of MSAS-Caregiver and MSAS-Teen was largely supported. Further work on MSAS-Child is warranted.
  We investigated the feasibility and safety of a framerate of 1 frame per second ("fps") for fluoroscopy and cine-angiography, to lower radiation exposure for patients and personnel in cardiac electrophysiology ("EP").
 
  Analysis of 2521 EP procedures, 899 (36%) with the lowest available conventional framerate (3.75 fps) and 1622 (64%) procedures performed with a framerate lowered further to 1.0 fps (by looping a 1Hz square pulse to the ECG trigger) performed between 01/2016 and 01/2020.
 
  Procedures performed with 1.0 fps had the same acute procedural success rates (p=0.20) and adverse event rates (p=0.34) as the 3.75 fps group. There was no difference in total X-ray operation time (p=0.40). The dose-area-product (DAP) was significantly reduced from 638 to 316cGy*cm
  (p<< 0.0001) for all procedure types together, and for each subgroup. In a multivariable linear regression model, total X-ray operation time (estimate 38cGy*cm
  /min) and body mass index (estimate 32cGy*cm
  / index point) and a framerate of 1.0 fps (-314cGy*cm
  against 3.75 fps) were independent predictors of a lower DAP (p-value of t-statistic for all < 0.0001).
 
  A framerate of 1.0 fps is safe and feasible in cardiac electrophysiology procedures. It was associated with a significant reduction of radiation exposure for patient and personnel.
 A framerate of 1.0 fps is safe and feasible in cardiac electrophysiology procedures. It was associated with a significant reduction of radiation exposure for patient and personnel.
  Drug-coated balloons (DCB) have demonstrated satisfactory clinical results in the treatment of femoropopliteal artery diseases.
 
  To evaluate the efficacy and safety of the Reewarm™ PTX DCB in the treatment of femoropopliteal artery lesions compared with plain balloon.
 
  This was a multi-center, parallel-group, randomized controlled trial in patients with femoropopliteal artery lesions in China,. The participants were randomized 11 to percutaneous transluminal angioplasty with Reewarm™ PTX DCB or with standard plain balloon (PTA group) after pre-dilatation with a residual stenosis less than 70%. The primary endpoint was late lumen loss (LLL) at 6months in the intent-to-treat set. The secondary endpoints included the target lesion revascularization (TLR) and major advance events(MAE)rate at 12months.
 
  Between July 2014 and April 2017, a total of 200 patients were enrolled. The mean age of the subjects was 67.8±9.2years in the DCB group (n=100) and 69.4±10.3years in the PTA group (n=100). The LLL at 6months in the DCB group was significantly lower than in the PTA group (0.5±0.8mm vs. 1.5±1.2mm, P<0.001). The TLR rate in the DCB group was lower than in the PTA group at 12months (15.0% vs. 29.0%, P<0.05). The occurrence of MAE
  in the DCB group by 12months was lower than in the PTA group (23.0% vs. 38.0%, P<0.05).
 
  Reewarm-PTX drug-coated balloon is associated with better efficacy and safety than the plain balloon for femoropopliteal lesion.
 Reewarm-PTX drug-coated balloon is associated with better efficacy and safety than the plain balloon for femoropopliteal lesion.
  The assessment and treatment of low relative muscle power in older people has received little attention in the clinical setting when compared to sarcopenia. Our main goal was to assess the associations of low relative power and sarcopenia with other negative outcomes in older people.
 
  The participants were 1189 subjects (54% women; 65-101years old) from the Toledo Study for Healthy Aging. Probable sarcopenia was defined as having low handgrip strength, while confirmed sarcopenia also included low appendicular skeletal muscle index (assessed by dual energy X-ray absorptiometry) (EWGSOP2's definition). Low relative (i.e. normalized to body mass) muscle power was assessed with the 5-repetition sit-to-stand power test (which uses an equation that converts sit-to-stand performance into mechanical power) and diagnosed in those subjects in the lowest sex-specific tertile. Low usual gait speed (UGS), frailty (according to Fried's criteria and the Frailty Trait Scale), limitations in basic (BADL) and instrumental aelative muscle power case finding in daily clinical practice was presented.Omega hydroxycarboxylic acids (ω-HAs) possess two functional groups, a hydroxyl group and a carboxyl group, and are essential precursors for the production of biodegradable polyester polymers. In this work, an Acidovorax mutant was investigated as a whole-cell biocatalyst for the conversion of cycloalkanes to their respective ω-hydroxycarboxylic acids. This Acidovorax sp. strain CHX100 originated from a wastewater treatment plant and uses cyclohexane as the sole source of carbon and energy with excellent growth rates (0.199 h-1). The metabolic efficiency of Acidovorax CHX100 is based on a highly efficient enzyme cascade used for the mineralization of cyclohexane. A deletion of 6-hydroxyhexanoate dehydrogenase in the native cycloalkane pathway resulted in the Acidovorax sp. strain CHX100 Δ6HX mutant, which accumulated short ω-hydroxycarboxylic acids (C5 to C10) from cycloalkanes. This mutant transformed cyclopentane and cyclohexane (5 mM) to 5-hydroxypentanoic acid and 6-hydroxyhexanoic acid, respectively, with a molar conversion above 98% in 6 h.